Search results
Results from the WOW.Com Content Network
Drug discontinuation may cause rebound effects (return of the symptoms the drug relieved, and that, to a degree stronger than they were before treatment first began) and withdrawal syndromes (symptoms caused by the discontinuation by the drug itself).
Discontinuing benzodiazepines or antidepressants abruptly due to concerns of teratogenic effects of the medications has a high risk of causing serious complications, so is not recommended. For example, abrupt withdrawal of benzodiazepines or antidepressants has a high risk of causing extreme withdrawal symptoms, including suicidal ideation and ...
The stopping of antidepressants for example, can lead to antidepressant discontinuation syndrome. With careful physician attention, however, medication prioritization and discontinuation can decrease costs, simplify prescription regimens, decrease risks of adverse drug events and poly-pharmacy, focus therapies where they are most effective, and ...
Changing your dosage or abruptly stopping your medication could cause you to experience antidepressant withdrawal symptoms like those electric shocks — also known as “brain zaps.” Switching ...
When stopped abruptly, Wellbutrin can cause withdrawal symptoms. If you develop side effects, it’s important not to make changes to your dosage or stop using Wellbutrin without first talking to ...
A drug holiday (sometimes also called a drug vacation, medication vacation, structured treatment interruption, tolerance break, treatment break or strategic treatment interruption) is when a patient stops taking a medication(s) for a period of time; anywhere from a few days to many months or even years if the doctor or medical provider feels it is best for the patient.
2. Eat Smaller, More Frequent Meals. Instead of three main meals, try eating smaller, more frequent meals throughout the day. This can help if nausea is making it hard to feel like eating or if ...
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.